Senti Biosciences
SNTI----
Q1 FY2026 EarningsSNTI announced a strategic spin-off of its clinical-stage asset SENTI-202 and Gene-Circuit pipeline to a NewCo controlled by Celadon. The deal unlocks up to $60M in milestone payments via Contingent Value Rights (CVR) for existing shareholders. Post-transaction, the company will focus on its proprietary Regulator Dial™ platform, targeting Rett Syndrome and solid tumors, while seeking additional financing to extend its runway.
Financial report interval: 2025.12.31 - 2026.03.31
Preview: Senti Biosciences(SNTI) predict that the Revenue is 16 K (--%), Beat estimate;the EBIT is -4.616 M (--%), Beat estimate;the EPS is -0.14 (--%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.00B--
0.00B--
+0.00B--%
EBITExceed expectations
-0.00B--
-0.01B--
+0.01B--%
EPSExceed expectations
-0.14--
-0.3333--
+0.1933--%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf